<DOC>
	<DOC>NCT02470403</DOC>
	<brief_summary>A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and normoglycemic patients with elevated body mass index (BMI)</brief_summary>
	<brief_title>Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<criteria>Subjects with stable health condition as determined by past medical history, physical examination, electrocardiogram, and laboratory tests at screening. Patients with dysglycemia are patients with: Fasting plasma glucose &gt;100mg/dL (5.6 mmol/L), or HbA1c &gt; 5.7% and &lt; 10% at screening. Fasting plasma glucose ≤250mg/dL (13.9 mmol/L) at screening. If treated with antidiabetic medications (other than prohibited medications), patients must be on a stable dose for 12 weeks prior to randomization and maintain the dose until the end of the study. Subjects must have a body mass index (BMI) within the range of 35 50 kg/m2 at screening, with stable body weight (± 5 kg) within 3 months prior to screening Preexisting, clinically significant gastrointestinal, liver, cardiovascular, renal or other chronic medical condition which is considered serious or unstable, other than stable cardiovascular disease, treated hypertension, dyslipidemia or other stable chronic disorders Clinically significant GI disorder related to malabsorption or that may affect drug or glucose absorption or history of significant gastrointestinal surgery that could affect intestinal glucose absorption Enrollment in a diet, weight loss or exercise programs with the specific intent of losing weight, within 3 months prior to randomization, or clinical diagnosis of any eating disorder Pregnant or nursing (lactating) women, and women of childbearing potential Other inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>dysglycemic, normoglycemic, prediabetes, type 2 diabetes mellitus</keyword>
</DOC>